BIOTEST AG (BIO.DE) Stock Fundamental Analysis
FRA:BIO - Deutsche Boerse Ag - DE0005227201 - Common Stock - Currency: EUR
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. While BIO is still in line with the averages on profitability rating, there are concerns on its financial health. BIO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past 5 years BIO reported 4 times negative net income.
In the past 5 years BIO reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.09%, BIO belongs to the top of the industry, outperforming 88.24% of the companies in the same industry.
The Return On Equity of BIO (12.99%) is better than 89.71% of its industry peers.
The Return On Invested Capital of BIO (5.87%) is better than 83.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.09% | ||
| ROE | 12.99% | ||
| ROIC | 5.87% |
ROA(3y)0.14%
ROA(5y)-0.57%
ROE(3y)-0.13%
ROE(5y)-1.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of BIO (9.69%) is better than 86.76% of its industry peers.
BIO's Profit Margin has declined in the last couple of years.
BIO has a better Operating Margin (12.62%) than 83.82% of its industry peers.
In the last couple of years the Operating Margin of BIO has grown nicely.
The Gross Margin of BIO (33.95%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of BIO has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.62% | ||
| PM (TTM) | 9.69% | ||
| GM | 33.95% |
OM growth 3YN/A
OM growth 5Y40.83%
PM growth 3YN/A
PM growth 5Y-16.36%
GM growth 3Y15.07%
GM growth 5Y3.99%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
Compared to 1 year ago, BIO has about the same amount of shares outstanding.
BIO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BIO has been reduced compared to a year ago.
2.2 Solvency
BIO has an Altman-Z score of 2.61. This is not the best score and indicates that BIO is in the grey zone with still only limited risk for bankruptcy at the moment.
BIO has a Altman-Z score of 2.61. This is in the better half of the industry: BIO outperforms 72.06% of its industry peers.
A Debt/Equity ratio of 0.82 indicates that BIO is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.82, BIO is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.82 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.61 |
ROIC/WACC0.97
WACC6.04%
2.3 Liquidity
BIO has a Current Ratio of 2.54. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a Current ratio of 2.54. This is comparable to the rest of the industry: BIO outperforms 51.47% of its industry peers.
BIO has a Quick Ratio of 2.54. This is a bad value and indicates that BIO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BIO (0.78) is worse than 77.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.70%, which is quite impressive.
Measured over the past years, BIO shows a decrease in Earnings Per Share. The EPS has been decreasing by -6.87% on average per year.
BIO shows a decrease in Revenue. In the last year, the revenue decreased by -8.51%.
The Revenue has been growing by 11.33% on average over the past years. This is quite good.
EPS 1Y (TTM)32.7%
EPS 3YN/A
EPS 5Y-6.87%
EPS Q2Q%-108.65%
Revenue 1Y (TTM)-8.51%
Revenue growth 3Y12.24%
Revenue growth 5Y11.33%
Sales Q2Q%-40.39%
3.2 Future
The Earnings Per Share is expected to decrease by -31.29% on average over the next years. This is quite bad
BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.49% yearly.
EPS Next Y-103.15%
EPS Next 2Y-31.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.17%
Revenue Next 2Y2.49%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 23.86, which indicates a rather expensive current valuation of BIO.
BIO's Price/Earnings ratio is rather cheap when compared to the industry. BIO is cheaper than 82.35% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.47. BIO is around the same levels.
A Price/Forward Earnings ratio of 26.93 indicates a quite expensive valuation of BIO.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 79.41% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 92.74. BIO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.86 | ||
| Fwd PE | 26.93 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BIO is valued a bit cheaper than 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.66 |
4.3 Compensation for Growth
The decent profitability rating of BIO may justify a higher PE ratio.
A cheap valuation may be justified as BIO's earnings are expected to decrease with -31.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.29%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOTEST AG
FRA:BIO (2/3/2025, 7:00:00 PM)
40.8
-1 (-2.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.61B
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.86 | ||
| Fwd PE | 26.93 | ||
| P/S | 2.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.06 | ||
| P/tB | 3.16 | ||
| EV/EBITDA | 17.66 |
EPS(TTM)1.71
EY4.19%
EPS(NY)1.52
Fwd EY3.71%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS17.87
BVpS13.33
TBVpS12.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.09% | ||
| ROE | 12.99% | ||
| ROCE | 8.34% | ||
| ROIC | 5.87% | ||
| ROICexc | 6.09% | ||
| ROICexgc | 6.18% | ||
| OM | 12.62% | ||
| PM (TTM) | 9.69% | ||
| GM | 33.95% | ||
| FCFM | N/A |
ROA(3y)0.14%
ROA(5y)-0.57%
ROE(3y)-0.13%
ROE(5y)-1.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y50.28%
ROICexc growth 3YN/A
ROICexc growth 5Y50.45%
OM growth 3YN/A
OM growth 5Y40.83%
PM growth 3YN/A
PM growth 5Y-16.36%
GM growth 3Y15.07%
GM growth 5Y3.99%
F-ScoreN/A
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.82 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.45 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.61 |
F-ScoreN/A
WACC6.04%
ROIC/WACC0.97
Cap/Depr(3y)77.8%
Cap/Depr(5y)86.44%
Cap/Sales(3y)4.7%
Cap/Sales(5y)5.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.7%
EPS 3YN/A
EPS 5Y-6.87%
EPS Q2Q%-108.65%
EPS Next Y-103.15%
EPS Next 2Y-31.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.51%
Revenue growth 3Y12.24%
Revenue growth 5Y11.33%
Sales Q2Q%-40.39%
Revenue Next Year-6.17%
Revenue Next 2Y2.49%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.85%
EBIT growth 3YN/A
EBIT growth 5Y56.78%
EBIT Next Year-53.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y48.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3YN/A
OCF growth 5YN/A